Invivyd starts Phase 2 FLINTLOCK trial of VYD2311 for long COVID, post-vaccination syndrome
IVVD•Invivyd launched a Phase 2 trial of VYD2311 for adults with long COVID or post-vaccination syndrome. The placebo-controlled trial will assess safety and potential clinical benefit over 90 days, with an initial readout expected in mid-2027.
1. Trial design and timing
The FLINTLOCK trial will assess VYD2311 against placebo in adults aged 18 to 65 with long COVID or post-vaccination syndrome. An initial readout is expected in mid-2027; no results have been presented.
